Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

NCT01240421 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01240421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01240421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Lead sponsor
Eisai Inc.
Phase
Expanded access
Overall status
Approved for marketing
Start date
March 31, 2011
Completion date
November 30, 2014
Enrollment
Not reported
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer